The Yale ADRC seeks to advance our understanding of Alzheimer's disease with the eventual goal of translating laboratory discoveries into novel effective clinical therapies. Five Cores (Administrative, Clinical, Data, Biomarker/Pathology and Outreach) and 3 Research Projects (Lysosomes, Post-Synaptic Densities and GABAergic Networks) will work together to achieve this goal. Our unifying theme is a focus on the cell biology of specific neurons, and its disruption in Alzheimer's disease triggered by abnormal forms of Amyloid-? peptide. Research Projects will focus on specific neuronal organelles and specific neuronal subtypes perturbed in disease and make use of human tissue analysis and human subject imaging to evaluate mechanistic hypotheses. The Biomarker/Pathology Core will develop novel, sensitive and high-throughput mass spectrometry assays by targeted multiple-reaction monitoring (MRM) to monitor disease mechanisms. A key emphasis will be the translational development of research findings into therapeutic benefit. To support the future strength of Alzheimer's research, the Yale ADRC will strive to advance the careers of Young Investigators through mentorship from a distinguished Internal Advisory Committee, and through Pilot Project awards. In addition to collecting clinical data and biospecimens of brain, CSF, DNA, serum, blood cells and iPSCs for analysis by members of the ADRC research team, the ADRC will support other Yale NIH-funded research studies on related topics and contribute materials to national NIA-sponsored research networks. The Outreach Core will connect with the community to provide greater knowledge regarding Alzheimer's disease and related dementia.
The Yale Alzheimer Disease Research Center (ADRC) seeks to advance our understanding of Alzheimer's disease with the eventual goal of translating laboratory discoveries into novel effective clinical therapies. Five Cores (Administrative, Clinica, Data, Biomarker/Pathology and Outreach) and 3 Research Projects (Lysosomes, Post-Synaptic Densities and GABAergic Networks) will work together to achieve this goal. Our unifying theme is a focus on the cell biology of specific neurons, and its disruption in Alzheimer's disease triggered by abnormal forms of Amyloid-? peptide.
|Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104|
|Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161|
|Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325|
|Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487|
|Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826|
|Salazar, Santiago V; Cox, Timothy O; Lee, Suho et al. (2018) Alzheimer's Disease Risk Factor Pyk2 Mediates Amyloid-? Induced Synaptic Dysfunction and Loss. J Neurosci :|
|MacNeil Vroomen, Janet L; Han, Ling; Monin, Joan K et al. (2018) Diabetes, Heart Disease, and Dementia: National Estimates of Functional Disability Trajectories. J Am Geriatr Soc 66:766-772|
|Gnjidic, Danijela; Agogo, George O; Ramsey, Christine M et al. (2018) The Impact of Dementia Diagnosis on Patterns of Potentially Inappropriate Medication Use Among Older Adults. J Gerontol A Biol Sci Med Sci 73:1410-1417|
|van Dyck, Christopher H (2018) Anti-Amyloid-? Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise. Biol Psychiatry 83:311-319|
|Kent, Brianne A; Strittmatter, Stephen M; Nygaard, Haakon B (2018) Sleep and EEG Power Spectral Analysis in Three Transgenic Mouse Models of Alzheimer's Disease: APP/PS1, 3xTgAD, and Tg2576. J Alzheimers Dis 64:1325-1336|
Showing the most recent 10 out of 134 publications